Compare DBI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBI | VYGR |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.2M | 227.2M |
| IPO Year | 2005 | 2015 |
| Metric | DBI | VYGR |
|---|---|---|
| Price | $7.65 | $3.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $6.75 | ★ $16.50 |
| AVG Volume (30 Days) | 411.0K | ★ 540.7K |
| Earning Date | 06-09-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | ★ 15.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,892,671,000.00 | $10,135,000.00 |
| Revenue This Year | $1.29 | $34.04 |
| Revenue Next Year | $1.88 | $7.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.18 | $2.83 |
| 52 Week High | $8.75 | $5.55 |
| Indicator | DBI | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 49.07 |
| Support Level | $7.15 | $3.71 |
| Resistance Level | $8.28 | $3.90 |
| Average True Range (ATR) | 0.38 | 0.23 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 76.55 | 44.09 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in two reportable segments: the Retail segment and the Brand Portfolio segment. The Retail segment, which derives key revenue, operates the DSW Designer Shoe Warehouse ("DSW") banner through its direct-to-consumer stores and e-commerce sites in the United States ("U.S.") and Canada, and the Shoe Co. and Rubino banners through its direct-to-consumer stores and e-commerce sites in Canada. The Brand Portfolio segment principally earns revenue from the wholesale of its exclusive and licensed brands to retailers, its Retail segment, and international distributors, and the sale of its Vince Camuto, Keds, and Topo brands through direct-to-consumer e-commerce sites.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.